Abstract
International hypertension guidelines endorse the use of combination therapy to achieve blood pressure control in the majority of patients. Angiotensin AT1 receptor blockers, in combination with diuretics, are among the preferred combinations, with telmisartan plus hydrochlorothiazide (HCTZ) being an effective and well-tolerated combination. This article provides an up-to-date review of the existing data on telmisartan/HCTZ combination for the management of hypertension in patients with additional cardiovascular risk factors, including reports emerging from a number of recent clinical trials and secondary analyses of older trials. The accumulated evidence from clinical trials demonstrates that telmisartan/HCTZ combinations are effective and well tolerated in patients with mild-to-severe hypertension, including subgroups of patients with cardiovascular risk factors such as advanced age, obesity, chronic kidney disease, diabetes mellitus and treatment-resistant hypertension.
| Original language | English |
|---|---|
| Pages (from-to) | 673-682 |
| Number of pages | 10 |
| Journal | Expert Review of Cardiovascular Therapy |
| Volume | 11 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 2013 |
Fingerprint
Keywords
- diabetes mellitus
- high cardiovascular risk
- hydrochlorothiazide
- hypertension
- obesity
- renal impairment
- telmisartan
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Internal Medicine
Cite this
An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors. / Kjeldsen, Sverre; Mancia, Giuseppe; Schmieder, Roland; Mattheus, Michaela; Unger, Thomas.
In: Expert Review of Cardiovascular Therapy, Vol. 11, No. 6, 06.2013, p. 673-682.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors
AU - Kjeldsen, Sverre
AU - Mancia, Giuseppe
AU - Schmieder, Roland
AU - Mattheus, Michaela
AU - Unger, Thomas
PY - 2013/6
Y1 - 2013/6
N2 - International hypertension guidelines endorse the use of combination therapy to achieve blood pressure control in the majority of patients. Angiotensin AT1 receptor blockers, in combination with diuretics, are among the preferred combinations, with telmisartan plus hydrochlorothiazide (HCTZ) being an effective and well-tolerated combination. This article provides an up-to-date review of the existing data on telmisartan/HCTZ combination for the management of hypertension in patients with additional cardiovascular risk factors, including reports emerging from a number of recent clinical trials and secondary analyses of older trials. The accumulated evidence from clinical trials demonstrates that telmisartan/HCTZ combinations are effective and well tolerated in patients with mild-to-severe hypertension, including subgroups of patients with cardiovascular risk factors such as advanced age, obesity, chronic kidney disease, diabetes mellitus and treatment-resistant hypertension.
AB - International hypertension guidelines endorse the use of combination therapy to achieve blood pressure control in the majority of patients. Angiotensin AT1 receptor blockers, in combination with diuretics, are among the preferred combinations, with telmisartan plus hydrochlorothiazide (HCTZ) being an effective and well-tolerated combination. This article provides an up-to-date review of the existing data on telmisartan/HCTZ combination for the management of hypertension in patients with additional cardiovascular risk factors, including reports emerging from a number of recent clinical trials and secondary analyses of older trials. The accumulated evidence from clinical trials demonstrates that telmisartan/HCTZ combinations are effective and well tolerated in patients with mild-to-severe hypertension, including subgroups of patients with cardiovascular risk factors such as advanced age, obesity, chronic kidney disease, diabetes mellitus and treatment-resistant hypertension.
KW - diabetes mellitus
KW - high cardiovascular risk
KW - hydrochlorothiazide
KW - hypertension
KW - obesity
KW - renal impairment
KW - telmisartan
UR - http://www.scopus.com/inward/record.url?scp=84878832614&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878832614&partnerID=8YFLogxK
U2 - 10.1586/erc.13.63
DO - 10.1586/erc.13.63
M3 - Article
VL - 11
SP - 673
EP - 682
JO - Expert Review of Cardiovascular Therapy
JF - Expert Review of Cardiovascular Therapy
SN - 1477-9072
IS - 6
ER -